How much funding has AviadoBio raised?

AviadoBio has raised $168.5M in total funding, most recently a Series B round.

Who are AviadoBio's investors?

AviadoBio's investors include Advent Life Sciences, New Enterprise Associates, Monograph Capital, F-Prime Capital, Dementia Discovery Fund, LifeArc.

Where is AviadoBio headquartered?

AviadoBio is headquartered in London, United Kingdom.

What industry is AviadoBio in?

AviadoBio operates in Biotech, Genomics, Life Sciences, Therapeutics, Healthcare.

How many employees does AviadoBio have?

AviadoBio has 51-200 employees.

AviadoBio

Relentlessly chasing cures through groundbreaking science

London, United Kingdom · Founded 2021 · $168.5M raised

Headquarters: London
Employees: 51–200
Founded: 2021
Business Model: B2B

Website: aviadobio.com
Total Funding: $168.5M
Last Round: $72.0M Series BApr 2025
Rounds: 3

About

AviadoBio is a clinical-stage gene therapy company building on research from King's College London and UK Dementia Research Institute to develop potentially one-time treatments for neurodegenerative diseases. Uses engineered AAV vectors and proprietary vMiX RNA silencing. Lead program AVB-101 targets Frontotemporal Dementia caused by GRN mutations.

Summary

AviadoBio is a Biotech company based in London, United Kingdom, founded in 2021. It has raised $168.5M in total across 3 rounds, most recently a $72.0M Series B round in Apr 2025. Investors include Advent Life Sciences, New Enterprise Associates and Monograph Capital.

LinkedIn X (Twitter)